A Berlin study of patients with early-stage colon cancer / DNA repair mechanisms and MACC1 gene activity helps determine prognosis and predict response to chemotherapy
Early-stage colon cancer patients could benefit in the future from specific genetic tests that forecast their prognosis and help them make the right decision regarding chemotherapy.
Two of the biomarkers involved are the MACC1 gene, high levels of which promote aggressive tumor growth and the development of metastasis, and a defective DNA mismatch repair (dMMR) system, which plays a role in tumor formation. Life expectancy is longer for patients with dMMR tumors and with low MACC1 gene activity.
Blood tests can help predict chemotherapy success
Colon cancer is the second most common type of cancer in Germany, affecting around 60,000 male and female patients every year. The five-year survival rate averages 70 percent. Treatment success is largely dependent on whether the tumor is detected early on, whether it can be completely surgically removed, and whether it responds to chemotherapy.
In recent years, scientists have successfully identified genetic subtypes of malignant colon tumors, all of which carry a different prognosis for how the disease will develop. Up to 15 percent of these malignant tumors, for example, exhibit defective DNA repair mechanisms – known as DNA mismatch repair deficiency or dMMR.
Another important biomarker is the gene MACC1 (metastasis-associated in colon cancer 1), which was identified by Ulrike Stein and her colleagues at MDC in 2009. There is now a patented blood test for MACC1 detection.
The five-year survival rate for patients with stage I-III colon cancer who exhibit low levels of MACC1 lies at 80 percent – in comparison to just 15 percent for patients with high MACC1 levels. “The blood test can indicate whether there is a higher risk of the tumor returning or metastasizing,” says Stein. “It helps with the difficult decision of whether early-stage patients should receive chemotherapy.” This now also includes patients in stage II of the disease with impaired DNA repair mechanisms.
In an editorial, also published in Annals of Oncology, scientists at Houston’s MD Anderson Cancer Center quote this study as further proof of how important it is to identify genetic subtypes and subtype combinations even in the early stages of the cancer, not least to help with prognosis and decisions regarding chemotherapy. They recommend that, in the future, genetic test results should be combined with further genetic and epigenetic data from patients, “in order to understand the prognostic value of the complex molecular scenarios of early-stage colon cancer.”
The Max Delbrück Center for Molecular Medicine (MDC)
The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) was founded in Berlin in 1992. It is named for the German-American physicist Max Delbrück who was awarded the 1969 Nobel Prize in Physiology and Medicine. The MDC’s mission is to study molecular mechanisms in order to understand the origins of disease and thus be able to diagnose, prevent and fight it better and more effectively.
In these efforts the MDC cooperates with the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health (BIH) as well as with national partners such as the German Center for Cardiovascular Research and numerous international research institutions. More than 1,600 staff and guests from nearly 60 countries work at the MDC, just shy of 1,300 of them in scientific research. The MDC is financed by the Federal Ministry of Education and Research (90 percent) and the State of Berlin (10 percent) and is a member of the Helmholtz Association of German Research Centres.
U.-P. Rohr, P. Herrmann, K. Ilm, H. Zhang, S. Lohmann, A. Reiser, A. Muranyi, J. Smith, S. Burock, M. Osterland, K. Leith, S. Singh, P. Brunhoeber, R. Bowermaster, J. Tie, M. Christie, H.-L. Wong, P. Waring, K. Shanmugam, P. Gibbs, U. Stein (2017): “Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.” Annals of Oncology. doi:10.1093/annonc/mdx207
https://insights.mdc-berlin.de/en/2017/07/biomarkers-identifying-tumor-aggressiv... – This media release at the website of the MDC
https://www.mdc-berlin.de/internet/1151921/ – Website of the Stein lab
https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdx207 – Publication at Annals of Oncology website
Annette Tuffs | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
How molecules teeter in a laser field
18.01.2019 | Forschungsverbund Berlin
Discovery of enhanced bone growth could lead to new treatments for osteoporosis
18.01.2019 | University of California - Los Angeles
The scientific and political community alike stress the importance of German Antarctic research
Joint Press Release from the BMBF and AWI
The Antarctic is a frigid continent south of the Antarctic Circle, where researchers are the only inhabitants. Despite the hostile conditions, here the Alfred...
World first experiments on sensor that may revolutionise everything from medical devices to unmanned vehicles
The new sensor - capable of detecting vibrations of living cells - may revolutionise everything from medical devices to unmanned vehicles.
Dead and alive at the same time? Researchers at the Max Planck Institute of Quantum Optics have implemented Erwin Schrödinger’s paradoxical gedanken experiment employing an entangled atom-light state.
In 1935 Erwin Schrödinger formulated a thought experiment designed to capture the paradoxical nature of quantum physics. The crucial element of this gedanken...
Cellulose obtained from wood has amazing material properties. Empa researchers are now equipping the biodegradable material with additional functionalities to produce implants for cartilage diseases using 3D printing.
It all starts with an ear. Empa researcher Michael Hausmann removes the object shaped like a human ear from the 3D printer and explains:
The phenomenon of so-called superlubricity is known, but so far the explanation at the atomic level has been missing: for example, how does extremely low friction occur in bearings? Researchers from the Fraunhofer Institutes IWM and IWS jointly deciphered a universal mechanism of superlubricity for certain diamond-like carbon layers in combination with organic lubricants. Based on this knowledge, it is now possible to formulate design rules for supra lubricating layer-lubricant combinations. The results are presented in an article in Nature Communications, volume 10.
One of the most important prerequisites for sustainable and environmentally friendly mobility is minimizing friction. Research and industry have been dedicated...
16.01.2019 | Event News
14.01.2019 | Event News
12.12.2018 | Event News
18.01.2019 | Materials Sciences
18.01.2019 | Life Sciences
18.01.2019 | Health and Medicine